In today’s rapidly changing healthcare world, nurses are stepping into roles that go far beyond traditional bedside care. With the healthcare system becoming increasingly interconnected and innovation reshaping how care is delivered, new opportunities are emerging that allow nurses to use their clinical expertise in areas once reserved for scientists, researchers, and corporate professionals. One…
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, and Animal Health. Check out our full report below:
Teva Reports the Data from the P-IV (PEARL) Study of Ajovy (fremanezumab) for Chronic and Episodic Migraine Prevention
Read More: Teva
Merck Reports the Data from P-III (HYPERION)…
Shots:
Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood
PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
Shots:
PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA
The May 2025 report covers designations granted to 44 drugs and 5 medical devices, spanning 15 small molecules, 7 biologics, 13 cell and gene therapies & 5 medical devices among others …
Precision Medicine in Cancer Treatment: Revolutionizing Patient Care Through Personalized Approaches
Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…
Shots:
At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria
The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab
PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, Animal Health & DigiHealth. Check out our full report below:
Johnson & Johnson Reports P-II (RedirecTT-1) Trial Data on Talvey + Tecvayli for R/R Multiple Myeloma
Read More: J&J
Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for…
Shots:
Nutraceuticals offer significant health benefits by enhancing body function and supporting body repair and growth
In 2024, the global nutraceuticals market is valued at $458.55B and is projected to rise to $986.85B by 2032, growing at a CAGR of 10.18%. Nestlé leads the market with reported segment revenue of $16.75B, followed by Danone and…
Shots:
In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL
Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression
PharmaShots welcomes Dr. Ira Zackon,…
Shots:
The EMA’s CHMP has granted positive opinions and approvals to 4 Biologics and 2 New Chemical Entites in May 2025, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were GSk’s Blenrep to Treat R/R Multiple Myeloma
PharmaShots has compiled a list of 4 drugs that have been…

